Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized‐controlled trial
暂无分享,去创建一个
P. Burbaud | W. Poewe | A. Ceballos-Baumann | M. Bareš | J. Ferreira | A. Belova | M. Banach | W. Jost | E. Ehler | G. Castelnovo | K. Bihari | L. A. Dzyak | A. Potulska‐Chromik | P. Picaut | W. Liu | Emmanuel Pham
[1] B. Mohammadi,et al. A long-term follow-up of botulinum toxin A in cervical dystonia , 2009, Neurological research.
[2] W. Jost,et al. Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia , 2012, Drugs.
[3] R F Galbraith,et al. A note on graphical presentation of estimated odds ratios from several clinical trials. , 1988, Statistics in medicine.
[4] A. Albanese,et al. EFNS guidelines on diagnosis and treatment of primary dystonias , 2011, European journal of neurology.
[5] S. Keam,et al. Botulinum Toxin A (Dysport®) , 2011, Drugs.
[6] M. Brin,et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. , 1999, Neurology.
[7] A. Kupsch,et al. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[8] C. Sampaio,et al. Botulinum toxin type B for cervical dystonia. , 2005, The Cochrane database of systematic reviews.
[9] R. Barbano,et al. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. , 2008, Neurologic clinics.
[10] J. Jankovic,et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia , 2011, Journal of the Neurological Sciences.
[11] J. Jankovic,et al. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. , 2007, Parkinsonism & related disorders.
[12] J. Hubble,et al. AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies , 2013, Journal of Neural Transmission.
[13] E. Pappert,et al. Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trial , 2008, Movement disorders : official journal of the Movement Disorder Society.
[14] S. Factor,et al. Effect of cervical dystonia on employment: A retrospective analysis of the ability of treatment to restore premorbid employment status , 2009, Movement disorders : official journal of the Movement Disorder Society.
[15] N. Panjwani,et al. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use , 2008 .
[16] M. Brin,et al. Efficacy, Tolerability, and Immunogenicity of OnabotulinumtoxinA in a Randomized, Double-Blind, Placebo-Controlled Trial for Cervical Dystonia , 2012, Clinical neuropharmacology.
[17] J. Jankovic,et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia , 2005, Neurology.
[18] J. Jankovic,et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study , 2005, Movement disorders : official journal of the Movement Disorder Society.
[19] J. Jankovic,et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. , 2010, Parkinsonism & related disorders.
[20] M. Brin,et al. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia , 2014, BMC Neurology.
[21] J. Jankovic,et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. , 1999, Neurology.